MAXCYTE, INC.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

Unaudited Condensed Consolidated Statements of Cash Flow****s

(in thousands)


· Six Months Ended June 30, ·
· · 2025 · 2024 ·
Cash flows from operating activities: · ·
Net loss	$(22,618)	$(18,901)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,196	2,192
Lease right-of-use asset amortization	378	233
Net book value of consigned equipment sold	55	21
Loss on disposal of property and equipment	113	361
Stock-based compensation	6,553	6,579
Credit loss expense (recovery)	10	(130)
Change in excess/obsolete inventory reserve	165	137
Amortization of discounts on investments	(1,635)	(3,665)

Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	(1,077)	1,327
Inventory	754	833
Prepaid expense and other current assets	773	1,322
Other assets	(1,140)	(321)
Accounts payable, accrued expenses and other	(5,340)	(3,497)
Operating lease liability	(593)	(215)
Deferred revenue	(2,831)	(1,701)
Other liabilities	(26)	27
Net cash used in operating activities	(24,263)	(15,398)

Cash flows from investing activities:
Purchases of investments	(63,523)	(79,353)
Maturities of investments	77,600	85,440
Purchases of property and equipment	(1,237)	(1,098)
Acquisition of business, net of cash acquired of $541	(1,773)	—
Net cash provided by investing activities	11,067	4,989

Cash flows from financing activities:
Proceeds from exercise of stock options	403	1,151
Proceeds from issuance of common stock under employee stock purchase plan	134	265
Net cash provided by financing activities	537	1,416
Net decrease in cash and cash equivalents	(12,659)	(8,993)
Cash and cash equivalents, beginning of period	27,884	46,506
Cash and cash equivalents, end of period	$15,225	$37,513

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses	$91	$80

MaxCyte, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(in thousands, except par value, share and per share amounts)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.